Summary: Welcome to this special ECTRIMS edition of RealTalk MS. Today, we're talking about pharmaceutical company Novartis seeking approval from the U.S. Food & Drug Administration and the European Medicines Agency for siponimod, a once-daily oral medication that significantly reduces disability progression for people living with secondary progressive MS. You'll also hear my conversation with the Chair of ECTRIMS 2018, Professor Reinhard Hohfeld. We have a lot to talk about! Are you ready for RealTalk MS?!
